JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Начало・Списък с акции・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

1.69 1.2

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.67

Максимум

1.75

Ключови измерители
By Trading Economics
Приходи	-2.8M -16M
Продажби	-8.7M 5.5M
Марж на печалбата	-282.723
Служители	81
EBITDA	-4.2M -15M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+127.98% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	128M 780M
Предишно отваряне	0.49
Предишно затваряне	1.69

Настроения в новините

By Acuity

50%

157 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.6863 / 0.72 Подкрепа & съпротива

Lexicon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.04.2026 г., 23:15 ч. UTC

Значими събития в новините

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27.04.2026 г., 23:08 ч. UTC

Печалби

Значими двигатели на пазара

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27.04.2026 г., 23:58 ч. UTC

Печалби

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27.04.2026 г., 23:58 ч. UTC

Печалби

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27.04.2026 г., 23:56 ч. UTC

Печалби

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27.04.2026 г., 23:56 ч. UTC

Печалби

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27.04.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27.04.2026 г., 23:42 ч. UTC

Пазарно говорене

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27.04.2026 г., 23:30 ч. UTC

Пазарно говорене

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27.04.2026 г., 23:08 ч. UTC

Пазарно говорене

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27.04.2026 г., 23:02 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.04.2026 г., 23:02 ч. UTC

Пазарно говорене

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27.04.2026 г., 22:42 ч. UTC

Пазарно говорене

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27.04.2026 г., 22:10 ч. UTC

Печалби

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27.04.2026 г., 21:56 ч. UTC

Печалби

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27.04.2026 г., 21:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27.04.2026 г., 21:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27.04.2026 г., 21:44 ч. UTC

Печалби

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27.04.2026 г., 21:43 ч. UTC

Печалби

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27.04.2026 г., 21:41 ч. UTC

Печалби

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27.04.2026 г., 21:41 ч. UTC

Печалби

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.04.2026 г., 20:39 ч. UTC

Печалби

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Сравнение с други в отрасъла

Ценова промяна

Lexicon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

127.98% нагоре

12-месечна прогноза

Среден 3.83 USD 127.98%

Висок 6 USD

Нисък 1 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Lexicon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Lexicon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.6863 / 0.72Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Настроение

By Acuity

157 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.